"Atypical" neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes

Harvard Review of Psychiatry

Volumn 15, Issue 4, 2007, Pages 181-186

  Choi Kain, Lois Wonsun ^a   Pope, Harrison Graham ^b  

^a MCLEAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CARBAMAZEPINE; CLONAZEPAM; DIPHENHYDRAMINE; HALOPERIDOL; HYDROXYZINE; LITHIUM CARBONATE; LORAZEPAM; PHENOBARBITAL; QUETIAPINE; VALPROATE SEMISODIUM;

ADOLESCENT; ARTICLE; BRAIN RADIOGRAPHY; CASE REPORT; DRUG DOSE INCREASE; ELECTROCONVULSIVE THERAPY; HUMAN; MALE; MANIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TEMPERATURE MEASUREMENT; VITAL SIGN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRAIN; HALOPERIDOL; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 34547739649     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220701551110     Document Type: Article

References (41)

1. Mann SC, Caroff SN, Keck PE, Lazarus A. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, DC: American Psychiatric Press, 2003.
2. Delay J, Pichot P, Lempiere T, Elissalde B, Peigne F. Un neuroleptique majeur nonphenothiazine et nonreserpine, l'haloperidol, dans le traitement des psychoses. Ann Med Psychol (Paris) 1960;118:145-52.
3. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-33.
4. Caroff SN, Mann SC, Lazarus A, et al. Neuroleptic malignant syndrome. Psychiatr Ann 1991;21:130-47.
5. Levenson J. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: APA, 2000.
7. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
8. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:314-21.
9. Caroff SN. Neuroleptic malignant syndrome: still a risk, but which patients may be in danger? Curr Psychiatry Online 2003;2(12):36-42.
10. Bristow MF, Kohen D. Neuroleptic malignant syndrome: may be caused by other drugs [Letter]. BMJ 1994;308:200.
11. Ohkoshi N, Satoh D, Nishi M, Shoji S. Neuroleptic malignant-like syndrome due to donepezil and maprotiline. Neurology 2003;60:1050-1.
12. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22:1-19.
13. Haddow AM, Harris D, Wilson M, Logie H. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. BMJ 2004;329:1333-5.
14. Hasan B, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-6.
15. Clark T, Anath J, Dubin S. On the early recognition of neuroleptic malignant syndrome. Intl J Psychiatry Med 1985-1986;15:299-311.
16. Misiaszek JJ, Potter RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985;26:62-3.
17. Adityanjee SS, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988;153:107-11.
18. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15:365-71.
19. Haggarty JM, Husni M, Peat C, Allain S. Atypical neuroleptic malignant syndrome? [Letter]. Can J Psychiatry 1999;44:711-2.
20. Newman M, Adityanjee SS, Jampala, C. Atypical neuroleptic malignant syndrome associated with risperidone treatment [Letter]. Am J Psychiatry 1997;154:1475.
21. Kohen D, Bristow MF. Atypical antipsychotics and neuroleptic malignant syndrome [Comment]. Br J Psychiatry 1999;175:392-3.
22. Ferioli V, Manes A, Melloni C, Nanni S, Boncompagni G. Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene [Letter]. Can J Psychiatry 2004;49:497-8.
23. Pope HG Jr, Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 1985;142:491-2.
24. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-21.
25. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104.
26. Ponto LB, Perry PJ, Liskow BI, Seaba HH. Drug therapy reviews: tricyclic antidepressant and monoamine oxidase inhibitor combination therapy. Am J Hosp Pharm 1977;34:954-61.
27. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
28. Parrott AC. MDMA (3,4-methylenedioxymethamphetamine) or ectasy: the neuropsychobiological implication of taking it at dances and raves. Neuropsychobiology 2004;50:329-35.
29. Rosenberg H, Davis M, James D, Pollack N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.
30. Adnet P, Lestavel P, Krisovic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35.
31. Gronert GA. Malignant hyperthermia. Anesthesiology 1980;53:395.
32. Gronert GA, Pessah IN, Muldoon SM, Tautz TJ. Malignant hyperthermia. In: Miller RD. ed. Miller's anesthesia. 6th ed., vol. 1. Philadelphia: Elsevier, 2005:1169-90.
33. Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am J Psychiatry 1996;143:1374-81.
34. Fricchione GL, Huffman JC, Stern TA, Bush G. Catatonia, neuroleptic malignant syndrome, and serotonin syndrome. In: Stern TA, Fricchione GL, Cassem NH, Jellinek MS, Rosenbaum JF, eds. Handbook of general hospital psychiatry. 5th ed. Philadelphia: Mosby, 2004:513-30.
35. Caroff SN, Mann SC, Keck PE, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000;20:257-9.
36. Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499-507.
37. Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome [Comment]. J Clin Psychiatry 2005;66:134.
38. Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am JMed Genet B Neuropsychiatr Genet 2003;117:57-60.
39. Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K. Asssociation in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor genes. Mol Psychiatry 2004;9:293-8.
40. Keck PE, Pope HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-2.
41. Kerwin RW, Osborne S, Sainz-Fuertes R. Heat stroke in schizophrenia during clozapine treatment: rapid recogntion and management. J Psychopharmacol 2004;18:121-3.